Red: stable co-clustering Blue: no co-clustering

Slides:



Advertisements
Similar presentations
H1299 Vector H1648 TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector H1648 TUSC2 TUSC2 -ER 2.3 uM ER H1299 Vector TUSC2 TUSC2.
Advertisements

945 Kb Kb 1,900 Kb 1,640 Kb 1,120 / 1,100 Kb 815 Kb 450 Kb 915 Kb 680 Kb 555 Kb 610 Kb
Supplementary Figure 1. Characterization of NPC1 knockdown hESC lines. (A) Knockdown of NPC1 measured by qRT-PCR in four clonal NPC1 hESC lines. NPC1 levels.
D Day 2Day 1Day 4Day 6 Day 1 Day 2 Day 4 Day 6 Biopsy Injury D0 D1 D2 D3 D4 D5 D6 Wound monitoring by endoscope & Intrarectal adminstration of LGG or HBSS.
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Volume 206, Issue 3, Pages (March 2013)
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Rupp et al. Supplementary Figure 1: Structure of the human troponin T gene Exon 6 Genomic DNA cDNA from mRNA mutation Exon 9 Exon bp Parts of genomic.
Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.
Volume 21, Issue 3, Pages (March 2012)
SI-II A SI-II. Expression analysis of bladder cancer functionally active genes and significantly mutated genes. Comprehensive transcriptome profiling of.
Volume 9, Issue 2, Pages (August 2017)
A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS
Figure 2. Co-expression of mutant proteins with wt cx26
Hypocotyl length (cm) WT bzs1-D bzr1-1D In the Dark Red Light
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
Supplemental Figures Supplemental Figure 1.
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Fig. S1 PIPKI is highly expressed in cancer cell lines
Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J
An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients  Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.
Supplementary Figure 2 Secondary transplanted brain tumors from PASC1 express human GH. Immuno-fluorescence staining of brain sections from mice implanted.
WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)
Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl
c-Jun Is Essential for Organization of the Epidermal Leading Edge
Volume 21, Issue 9, Pages (November 2017)
Supplemental Material
Supplemental Figure 1 A B C
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
Volume 44, Issue 4, Pages (November 2011)
Volume 11, Issue 6, Pages (June 2012)
Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.
Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases  Yi-Lin Chen, Cheng-Chan Lu, Shu-Ching.
The ΔrlmA mutant strain has impaired CWI pathway activation.
Supplemental Figure 1 a b c d.
Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.
Volume 9, Issue 2, Pages (August 2017)
Supplementary Figure S1
Dynamics of Inductive ERK Signaling in the Drosophila Embryo
Volume 21, Issue 3, Pages (March 2012)
Kindlin-1 Regulates Epidermal Growth Factor Receptor Signaling
Distinct Autophagosomal-Lysosomal Fusion Mechanism Revealed by Thapsigargin- Induced Autophagy Arrest  Ian G. Ganley, Pui-Mun Wong, Noor Gammoh, Xuejun.
Volume 20, Issue 3, Pages (March 1998)
Volume 17, Issue 9, Pages (November 2016)
Volume 7, Issue 3, Pages (September 2010)
Time course of Fim1-GFP appearance and disappearance in actin patches.
Volume 143, Issue 1, Pages (October 2010)
Supplementary Figure 1 ** ** _ _ + + a. b. ** ** _ _ + + c. n=3 RU486
Volume 20, Issue 1, Pages (July 2017)
Experience-Dependent Equilibration of AMPAR-Mediated Synaptic Transmission during the Critical Period  Kyung-Seok Han, Samuel F. Cooke, Weifeng Xu  Cell.
EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer  Philip C. Mack,
c-Src Activates Endonuclease-Mediated mRNA Decay
CD28 Signaling via VAV/SLP-76 Adaptors
Rui Qin, Shuai Cao, Tianjie Lyu, Cai Qi, Weiguang Zhang, Yun Wang 
Chien-Wei Chen, MD, Chin-Wei Kuo, MD  Journal of Thoracic Oncology 
Molecular Therapy - Nucleic Acids
Ernest Nadal, MD, Guoan Chen, MD, PhD, John R
EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers
Volume 11, Issue 13, Pages (July 2001)
Volume 28, Issue 5, Pages (May 2008)
(B) HDR assay (6nt) (D) HDR assay (1nt)
Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.
Volume 1, Issue 2, Pages (February 2012)
Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.
Inter-laboratory cohort Prognostication cohort
Volume 23, Issue 10, Pages (June 2018)
EZH2-driven lung cancer as a molecularly distinct entity.
The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.
Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.
Presentation transcript:

Red: stable co-clustering Blue: no co-clustering Supplementary Figure 1 Red: stable co-clustering Blue: no co-clustering 2-cluster 3-cluster Results of NMF in 74 samples from the WG dataset These plots show how often each pair of samples (74x74 pairings) were in the same cluster during 20 iterations of NMF. Dark red means the samples were always in the same cluster and dark blue means they never were. There is support for 2, 3, and 4 stable cluster assignments by NMF. K5 and K6 are unstable. 4-cluster 5-cluster

Supplementary Figure 2

Supplementary Figure 3

Supplementary Figure 4 P=0.16 EGFR mutation

Supplementary Figure 5

Supplementary Figure 6 EGFR mutation KRAS mutation

26 10 16 14 5 7 17 104 n=199 DUSP4 deletion p16 deletion EGFR mutation Supplementary Figure 7 p=0.0001 DUSP4 deletion p16 deletion 26 10 16 14 5 7 p=0.00003 p=0.007 17 104 EGFR mutation n=199

Wild type EGFR EGFR del19 EGFR L858R Supplementary Figure 8 6E-16 Wild type EGFR EGFR del19 EGFR L858R 5E-16 4E-16 DUSP4 mRNA conc (uM) 3E-16 2E-16 1E-16 WT - No EGF WT - 2 hrs WT - 4 hrs WT - 30 min WT - 1 hr WT - 6 hrs del19 - No EGF del19 - 30 min del19 - 2 hrs del19 - 4 hrs del19 - 6 hrs L858R - No EGF del19 - 1 hr L858R - 30 min L858R - 2 hrs L858R - 4 hrs L858R - 1 hr L858R - 6 hrs

Supplementary Figure 9 A B GFP DUSP4-GFP H358 H1650 H1650 DUSP4 Vector 70KD DUSP4-GFP 27KD GFP ACTIN H358 H1650 H1650

Supplementary Figure 10 H1650 cells 24hrs after electroporation H1650 cells after one week selection GFP DUSP4-GFP